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Introduction: Ciclosporin A (CsA) is considered to be a major
component in the prophylaxis and treatment of acute and chronic
graft-versus-host-disease (GvHD) after allogeneic hematopoietic
stem cell transplantation (HSCT). However, impairment of renal
function and CNS toxicity may complicate or even inhibit the use
of calcineurin-inhibitors (CNI). Here, we report the use of siroli-
mus/MMF in two children with acute/chronic GvHD and signif-
icant CNI-associated toxicities. Case Reports: Two patients, a
14-year-old boy and a 4-year-old girl, were transplanted for ALL
and AML, respectively. They received bone marrow from their
HLA-identical siblings and GvHD-prophylaxis with MTX and
CsA. Patient 1, the boy, stayed on CsA until day 27, when he
complained of dizziness and disorientation. The cranial MRI ﬁnd-
ings were consistent with CsA-induced neurotoxicity. He was set
on tacrolimus until day 95, when he presented with cerebral
seizures and somnolence. In the absence of acute GvHD and the
presumption of tacrolimus-induced neurotoxicity, the drug was
discontinued. One week later, the presence of GvHD of skin and
gut could be conﬁrmed by biopsy. During his previous anti-leuke-
mic therapy, the patient had suffered from severe side effects of
high-dosed steroids. So, in an attempt to minimize the use of
steroids, he was set on sirolimus/MMF with a short course of
prednisone. He rapidly responded to this regimen. Steroids were
discontinued after a few days. The boy stayed on sirolimus/MMF
for four months without evidence of recurrent GvHD. Patient 2
was switched early to tacrolimus because of a status of stupor
and suspected CsA-neurotoxicity. She developed stage 4 gut
GvHD on day 45, responsive to a highly immunosuppressive
therapy including inﬂiximab. Eleven months post-transplant,
while on tacrolimus, she had increasing renal insufﬁciency with
a creatinine clearance of 30 ml/min and a urea of 120 mg/dl. She
was set on sirolimus/MMF; in the transition phase to that
regimen she had another, steroid-responsive ﬂare of her gut
GvHD. Eighteen months post-transplant, the girl’s GvHD is
under good control with sirolimus and low dose steroids. Renal
function tests are within normal limits. Conclusion: In HSCT
recipients with severe calcineurin-inhibitor neurotoxicity or im-
paired renal function, the use of sirolimus/MMF should be
considered when continuation of immunosuppressive therapy is
mandatory for control of GvHD.
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T CELLS OF RECIPIENT ORIGIN MEDIATE THE DEVELOPMENT OF
MURINE SYNGENEIC GRAFT-VERSUS-HOST DISEASE
Brandon, J.A.1, Jennings, C.D.2, Caywood, B.E.3, Perez, J.1,
Kaplan, A.M.1, Bryson, J.S.1,3 1. Department of Microbiology, Immu-
nology, and Molecular Genetics; 2. Department of Pathology; 3. Depart-
ment of Internal Medicine, Division of Hematology, Oncology and Blood
and Marrow Transplantation, University of Kentucky, Lexington, KY.
Syngeneic graft-versus-host disease (SGVHD), characterized
by a TH1 cytokine response, and intestinal inﬂammation devel-
ops following lethal irradiation, reconstitution with syngeneic
bone marrow, and treatment for 21 days with cyclosporine A
(CsA). It has generally been assumed that the T cell responses
associated with SGVHD resulted from the reconstitution of
irradiated recipients with donor bone marrow. However, to
determine the origin of the effector cells that mediate SGVHD,
syngeneic bone marrow from normal immunocompetent mice
or immunodeﬁcient mice were transferred into lethally irradi-
ated recipients. Following CsA treatment, mice within both
groups developed inﬂammation characteristic of SGVHD in the
colon and liver. Furthermore, increases in the expression of TH1
cytokines, levels of colonic CD4 T cells and expression of
activated peripheral CD4 T cells were comparable regardless
of whether CsA-treated animals received T cell sufﬁcient (nor-
mal) or T cell deﬁcient (SCID) bone marrow. These results
demonstrate that in the absence of donor T cells, recipient T
cells can expand and mediate the induction of CsA-induced
SGVHD.
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FATAL TUMOR LYSIS SYNDROME ASSOCIATED WITH INDUCTION OF
GRAFT-VS-HOST DISEASE IN A RELAPSED PATIENT WITH NASAL NK
CELL LYMPHOMA AFTER TANDEM AUTOLOGOUS–ALLOGENEIC STEM
CELL TRANSPLANTATION
Uryu, H.1, Koseki, M.1, Mori, Y.2, Niiya, D.3, Takeuchi, M.1,
Matsue, K.1 1. Kameda General Hospital, Internal Medicine, Depart-
ment of Hematology-Oncology, Kamogawa, Chiba Pref, Japan; 2. Ky-
ushu University, Fukuoka-City, Japan; 3. Okayama University,
Okayama-City, Japan.
The effective therapy for nasal natural-killer (NK) cell lym-
phoma is not established, and there is no report that the graft-
versus-lymphoma effect (GVLE) against the nasal NK cell lym-
phoma was deﬁnitively conﬁrmed. We report a patient with nasal
NK cell lymphoma who relapsed after allogeneic transplant and
developed fatal tumor lysis reaction during the attempt of inducing
graft-versus-host disease (GVHD). The patient was 53-year-old
woman suffering from a rapidly progressing nasal NK cell lym-
phoma metastasis to the skin, adrenal grand and abdominal lymph
nodes. She received three courses of combination chemotherapy
followed by high-dose therapy with a rescue of autologous haema-
topoietic stem cell transplant (HSCT). Following attainment of
partial remission, she underwent allogeneic HSCT from an HLA-
matched sibling prepared with reduced-intensity regimen and at-
tained complete remission. In the subsequent course, she had no
acute GVHD, but had extensive chronic GVHD mainly on skin,
requiring some immunosuppressions. Seven months after alloge-
neic HSCT, she developed fever and pancytopenia. A general
search revealed bone marrow relapse without any other lesion.
Immunosuppressions were tapered with expecting GVLE. Two
weeks after the withdrawal, she suddenly developed tachypnea.
Emergent laboratory data revealed signiﬁcant hyperkalemia, hy-
peruricemia, metabolic acidosis. We also found the marked de-
crease of tumor cells in a bone marrow aspiration specimen. After
the tumor lysis reaction, the patient developed severe renal and
hepatic dysfunction, causing her death despite intensive care. This
is the ﬁrst case report that deﬁnitely conﬁrmed a GVLE against
NKCL.
HISTOCOMPATIBILITY/ALTERNATIVE
STEM CELL SOURCES
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FACTORS PREDICT HEMATOPOIETIC RECOVERY IN PATIENTS WITH
FANCONI ANEMIA (FA) AFTER ALTERNATE DONOR (AD) HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT)
Al-Sweedan, S.A., Wagner, J.E., Tan, Y., DeFor, T.E.,
MacMillan, M.L. University of Minnesota, Minneapolis, MN.
As engraftment has been a signiﬁcant barrier to successful AD
HSCT (deﬁned as bone marrow [BM] or umbilical cord blood
[UCB] from a donor other than an HLA matched sibling), we
attempted to identify risk factors predictive of hematopoietic
recovery in this setting. Therefore, we evaluated engraftment in
83 FA patients aged 0.8–48.5 years (median 11.8) who under-
went T cell depleted BMT [(TCD, n  31), no TCD BMT (n 
37) or UCBT (n  15)] at the University of Minnesota from
1990 to 2004. 55% had aplastic anemia and 34% had myelodys-
plastic syndrome/acute myeloid leukemia at time of HSCT;
34% were CMV seropositive; 60% had HLA matched donors.
All received 40 mg/kg cyclophosphamide and 450 or 600 cGy
total body irradiation with 65% also treated with ﬂudarabine
(FLU) 140 mg/m2. BM Grafts contained 0.82–9.32  106CD34
cells/kg and 0.66–2.57  103 CD3 cells/kg and UCB grafts
contained 0.01– 0.91  106CD34 cells/kg and 0.03–0.24  103
CD3 cells/Kg. In univariate analysis, factors associated with
signiﬁcantly improved incidence of neutrophil recovery(	500/
uL) were no TCD-BM (94%) and TCD-BM in presence of
FLU (91%) compared to 83% and 68% in recipients of UCB
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and TCD-BM in absence of FLU (P  .01); recipient CMV
seronegative status (93% vs 69%, P  .02); HLA matched
donor-recipient pair (94% vs 69%, P  .01); negative transfu-
sion history (100% vs 83%, P  .05), and use of FLU in the
preparative regimen (94% vs 69% ,P  .01). Disease status at
HCT, androgen use, number of malformations, recipient age
and gender, mosaicism, and history of prior infections did not
have a demonstrable effect on neutrophil recovery. In multivar-
iate analysis, factors associated with improved neutrophil recov-
ery were CMV seronegative serostatus, HLA matched donor-
recipient pair and use of FLU (Table 1). Similarly, incidence of
platelet recovery (	20,000/uL) was signiﬁcantly higher in CMV
negative recipients (Relative Risk [RR] 2.46, 95% CI 1.16–5.22,
P  .02), HLA matched HSC (RR 3.1, 95% CI 1.39–6.82, P 
.01), and FLU (RR 10.8, 95% CI 2.82–41.3, P  .01). In
summary, hematopoietic recovery after AD HSCT in FA pa-
tients following FLU containing preparative regimens are com-
parable to those of HLA matched sibling donor BM recipients.
Therefore signiﬁcant practice changes should be considered
such as the use of a FLU containing preparative regimen,
particularly in the setting of TCD.
Table 1. Cox Regression on Primary Neutrophil Engraftment
Factors
Relative Risk
(95% CI) P-value
Model (X2  28.8, P < .01)
Recipient CMV
Positive* 1
Negative 1.95 (1.13–3.35) .02
HLA match
Mismatch* 1
Match 2.70 (1.59–4.60) .01
FLU
No* 1
Yes 2.10 (1.22–3.63) .01
*Note: reference category.
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LACK OF T CELL ALLOREACTIVITY TO CORD BLOOD MONONUCLEAR
CELLS
Chunduri, S., Mahmud, D., Abbasian, J., Rondelli, D. University of
Illinois at Chicago, Chicago, IL.
Transplantation of HLA-mismatched cord blood (CB) nucleated
cells has limited risk of graft rejection and severe acute graft-
versus-host disease. This may depend on naı¨ve T cells not yet
exposed to many antigens and/or on immature antigen-presenting
cells (APC) not delivering appropriate signals to allogeneic T cells.
In order to test the APC activity of human circulating CB cells in
vitro, we initially used irradiated CB mononuclear cells (MNC) or
immunomagnetically selected CD34 cells, CD133 cells, or
CD14 monocytes to stimulate the proliferative response of in-
compatible blood T cells in mixed leukocyte culture (MLC). CB
MNC failed to induce allogeneic T cell proliferation, while
CD34 and CD133 progenitors or CD14 monocytes induced
potent T cell alloresponses. Nevertheless, since allogeneic T cell
response was not restored after depletion of CD3 cells in the CB,
or the add-back of irradiated CB MNC to CD34 or CD14
stimulators inhibited allo-T cells, a direct suppressive effect of CB
MNC was excluded. Allogeneic peripheral blood cytotoxic T-
lymphocyte (CTL) responses were not induced after 7 days of
stimulation with irradiated CB MNC, although after 4 weekly
rechallenges with CB MNC, on average a 23% lysis of antigen-
speciﬁc CB PHA-blasts was observed at the highest effector:target
ratio (50:1). To test the tolerogenic potential of CB MNC, T cells
initially exposed to CB MNC were rechallenged in secondary
MLC with CB MNC, or CD34 cells, or monocyte-derived
dendritic cells (Mo-DC) generated in liquid culture with GM-CSF
and IL-4. Allogeneic T cells were still unresponsive upon rechal-
lenge with CB MNC, but proliferated upon 3 days of restimulation
with CD34 cells or Mo-DC from the same CB. These results
show an impaired allo-APC activity of CB MNC but not CB
CD34 cells, and suggest that although CB cells do not induce an
Ag-speciﬁc in vitro anergy, their weak APC activity may reduce the
risk of rejection in an HLA-mismatched stem cell transplant set-
ting. In addition, these ﬁndings may explain the initial engraftment
of two mismatched CB grafts, currently infused in CB transplant
protocols for adult patients.
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NO ASSOCIATION BETWEEN MIC-A POLYMORPHISM AND CLINICAL
OUTCOME AFTER ALLOGENEIC HSCT
Uzunel, M., Remberger, M. Karolinska Institutet, Clinical Immunology,
Stockholm, Sweden.
Background: MHC class I chain related molecule A (MIC-A)
shows homology with the classical HLA molecules. MIC-A is
polymorphic with more than 50 recognized alleles and is described
as a “marker of stress” since it is up-regulated on epithelial cells at
heat and virus infection. The presence of MIC-A antibodies in
patient sera has been associated with rejection after organ trans-
plantation. The signiﬁcance of MIC-A polymorphism in hemato-
poietic stem cell transplantation (HSCT) has not been studied. In
this study we wanted to see the degree of MIC-A mismatch be-
tween patients and donors and to investigate if the MIC-A geno-
type was associated with clinical outcome after HSCT. Materials
and Methods: For MIC-A genotyping, we performed PCR am-
pliﬁcation with allele-speciﬁc primers. A total of 248 leukemia
patients were included in the study. All received myeloablative
conditioning and GVHD prophylaxis consisted mainly of a com-
bination of cyclosporine A and methotrexate. In unrelated trans-
plants (149), both the patient and the donor were genotyped while
in sibling transplants (99) only the patient was genotyped. Results:
In unrelated transplants, 16 (11%) mismatches were found. Al-
though an increase in the incidence of chronic GVHD was found
among patients receiving a graft with MIC-A mismatch, there were
no signiﬁcant differences in leukemia free survival (LFS), trans-
plant related mortality (TRM) and GVHD between patients with
MIC-A match or mismatch. At the MIC-A allele level, no speciﬁc
allele was found to be associated with different clinical outcomes
after HSCT. Conclusion: MIC-A mismatch is a rare event in
HLA matched HSCT. Neither the MIC-A mismatch nor the
MIC-A alleles seem to have a major effect on the clinical outcome
after HSCT.
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HSCT FROM PARTIALLY MATCHED ALTERNATIVE DONORS—A SINGLE
CENTRE EXPERIENCE
Vitek, A.1, Cetkovsky, P.1, Dobrovolna, M.1, Ivaskova, E.2,
Korinkova, P.1, Kovarova, P.1, Kupkova, L.2, Loudova, M.1,
Markova, M.1, Matejkova, E.1, Navratilova, J.3, Pitrova, H.3,
Pohlreich, D.1, Sajdova, J.1, Sponerova, D.1, Valkova, V.1, Vrana, M.1,
Vytiskova, J.1 1. Institute of Hematology and Blood Transfusion, Prague,
Czech Republic; 2. Czech Marrow Donor Registry, Prague, Czech Re-
public; 3. Czech National Marrow Donor Registry, Pilsen, Czech Re-
public.
Increased amount of indications for alloBMT is connected with
increased demand for donors. For approximately 30% of the pa-
tients is possible to ﬁnd HLA identical sibling, for another 70% of
the patients is necessary to obtain graft from alternative donors.
Because it can be difﬁcult or even impossible to ﬁnd fully matched
alternative donors, that means donors identical in all 10 HLA
antigens typed on HR level of A, B, C, DRB1, and DQB1 loci, we
must often accept donors with some mismatches. We performed
182 transplantations from alternative donors between 1991 and
2005. 89 were mismatched for one or more HLA alleles or anti-
gens. Twenty-nine patients were transplanted for AML, 26 for
CML, 12 for ALL, 10 for MDS, 4 for CLL, 3 for MMM, 2 for
NHL, 2 for HD, and 1 for MM. Half of these patients were
transplanted in advanced stage of the disease. In 80% of the
patients, ATG-Fresenius was used in conditioning and 17% of the
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